Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Revenue (2016 - 2023)

Historic Revenue for Spyre Therapeutics (SYRE) over the last 7 years, with Q2 2023 value amounting to $688000.0.

  • Spyre Therapeutics' Revenue rose 1008.0% to $688000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $688000.0, marking a year-over-year decrease of 4094.42%. This contributed to the annual value of $886000.0 for FY2023, which is 6195.79% down from last year.
  • As of Q2 2023, Spyre Therapeutics' Revenue stood at $688000.0, which was up 1008.0% from $198000.0 recorded in Q1 2023.
  • Spyre Therapeutics' 5-year Revenue high stood at $12.0 million for Q2 2021, and its period low was $168000.0 during Q4 2022.
  • In the last 3 years, Spyre Therapeutics' Revenue had a median value of $688000.0 in 2023 and averaged $3.4 million.
  • Per our database at Business Quant, Spyre Therapeutics' Revenue plummeted by 9855.0% in 2022 and then surged by 1008.0% in 2023.
  • Over the past 3 years, Spyre Therapeutics' Revenue (Quarter) stood at $3.6 million in 2021, then plummeted by 95.39% to $168000.0 in 2022, then soared by 309.52% to $688000.0 in 2023.
  • Its Revenue stands at $688000.0 for Q2 2023, versus $198000.0 for Q1 2023 and $168000.0 for Q4 2022.